Friday,DECember 10, 2021

 

Neuromodulation in the management of heart failure and its comorbidities: diabetes, sleep apnea and hypertension


08:00 - 10:00  |  Ballroom

Translational concepts in the development of new treatment strategies     
    
Renal denervation for heart failure treatment: Renal denervation for HFpEF: trial design considerations - how can RDN learn from trials of inter-atrial shunt trials and SGLT-2 inhibitors     
    
Renal denervation for heart failure treatment: Renal denervation for HFrEF: how to design trials given all the other treatments available - where would RDN fit in this crowded space?     
    
Treatment of central sleep apnea in heart failure patients: Remede     
    
Update on electrical barostimulation     
    
Stent-based barostimulation: Results of the first in man trial     
    
An endovascular approach for treating HF patients using an implantable active Neuromodulation Implant     
    
Metavention: Renal and hepatic artery denervation to treat metabolic syndrome     
    
Vagus nerve stimulation     
    
Atrial fibrillation in heart failure

Pathogenesis and treatment of heart failure with preserved ejection fraction (HFpEF)


10:30 - 11:20  |  Ballroom

What are the underlying causes of HFpEF     
    
The many faces of HFpEF – not just one disease     
    
The failures, the learnings and the encouraging future - overview of potential therapies for HFpEF (medical therapy, clinical trial design, devices)     
    
What is the causal role for Tricuspid Regurgitation in HFpEF?

The splanchnic bed is a novel target in patients with heart failure with preserved ejection fraction (HFpEF) s


11:20 - 12:35  |  Ballroom

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF     
    
Long-term follow-up on FIH endovascular therapy using the Satera Ablation System in HFpEF and HFrEF     
    
Where does this therapy potentially fit into current landscape of treatments for HFpEF and HFrEF
    
Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF     
    
Proposed design of the worldwide Pivotal Clinical HF trial

Telemedicine


12:50 - 14:00  |  Ballroom

Telemedicine advancements during the COVID-19 pandemic: What's worked, what hasn't, and what's to come?     
    
Non-invasive assessment of lung fluid content     
    
Implantable Hemodynamic Monitors: CardioMEMS…     
    
Implantable Hemodynamic Monitors: The first in heart microcomputer for the management of HF patients     
    
Implantable Hemodynamic Monitors: Exercise stress testing in remote heart failure management     
    
Non-invasive assessment of fluid status and arrthymogenic     
    
Payer perspective

Durable mechanical circulatory support


14:00 - 15:10  |  Ballroom

Durable MCS state of the art     
    
CorWave LVAD - a biomimetic pump for physiologic pulsatility     
    
HeartMate 3      
    
Carmat Aeson LVAD  

Evaheart   
    
Impella 5.5

Impella BRT     
    
VADovations

Cardio Dyme

Acute mechanical circulatory support


15:40 - 17:10  | Ballroom

Acute MCS state of the art     
    
ECP EFS     

ProtekDuo in COVID ARDS
    
Aortix EFS     

SecondHeart

Puzzle

PreCardia EFS   

PreCardia clinical trial
    
New Impella RP    
    
IABP

Insights from the PULSE Trial & iVAC 2L in MCS facilitated high-risk PCI

New and upcoming concepts and devices


17:10 - 18:00  |  Ballroom

Synchronized diaphragmatic stimulation for the treatment of symptomatic heart failure       
    
Importance of mitral valve plane movement in heart pumping - updated insights     
    
Syntach - a novel minimally invasive cardiac support system      

Doraya
    
Targeting enhanced decongestion while aiming to preserve renal function – lymphatic-powered interstitial decongestion     
    
Percutaneous Pericardial Resection

Device Development Workshop


18:00 - 19:00  |  Ballroom

 

 

Saturday, DECember 11, 2021

 

E-poster presentation


07:00 - 08:00  |  Exhibition area

 

Electrotherapy for heart failure treatment


08:00 - 08:40  |  Ballroom

Cardiac contractility modulation     
    
CCM – Closing the gap: When OMT is not enough     
    
HIS Bundle stimulation     
    
New results from the landmark REVERSE trial: More patients may benefit from CRT therapy

Interventions for LV Reconstruction and support


08:40 - 09:40  |  Ballroom

Therapeutic opportunity & single center experience     
    
Predictors of Revivent LV restoration outcomes     
    
The AccuCinch Ventricular Restoration System     
    
Transcatheter intramyocardial hydrogel injection (XDrop): FIM results     
    
Percutaneous radiofrequency ablation of HOCM

Right heart failure


0940 - 10:50  |  Ballroom

Pathology and pathophysiology, clinical  relevance of RHF-does it help to treat TR?     
    
Evaluation of right ventricular function and its importance in RHF     
    
Right heart failure in the guidelines     
    
Mechanical assist in RHF using Impella RP     
    
Mechanical assist in RHF using the PERKAT RV pulsatile right ventricular support device     
    
PHT in RHF, monitoring and treatment     
    
Tricuspid trial for RHF: Haemodynamic perspective

Valve interventions in patients with heart failure


10:20 - 12:50  |  Ballroom

Introduction     
    
Recent innovations for the management of patients with valvular heart disease – focus on heart failure     
    
2021 European guidelines on heart failure – focus on heart valves     
    
Echo criteria to identify TEER responders beyond COAPT     
    
Volume outcome relation in percutaneous FMR treatment     
    
Role of the right sided heart in FMR     
    
The impact of tricuspid regurgitation on patient outcomes     
    
What do the guidelines say about tricuspid regurgitation?     
    
Status on transcatheter tricuspid valve interventions – when & how     
    
The current evidence and the vast clinical study & registry pipeline     
    
Case presentation: improving patient outcomes and QoL with a new device (PASCAL Ace)     
    
Prevalence, prognosis, and management of exercise-induced severe MR in patients with heart failure     
    
Closing remarks

Interatrial shunts


13:35 - 15:30  |  Ballroom

The physiological rationale for IASD as a treatment for heart failure     
    
Lessons learned and being learned from the Corvia Reduce LAP-2 Study     
    
IASD across the spectrum of EFs     
    
Are different size shunts required?     
    
Is a device implant necessary for effective interatrial shunt?     
    
Alternate means of creating a durable shunt without leaving a device behind: Noya     
    
Alternate means of creating a durable shunt without leaving a device behind: InterShunt     
    
Interatrial shunting for pulmonary hypertension     
    
Clinical trial considerations for IASD pivotal studies     
    
Interatrial shunt for end-stage amyloid heart disease (recorded case)

The future of device-based therapies and diagnostics for heart failure


16:00 - 17:20  |  Ballroom

CMO View
    
Cardiovascular innovations in Corona time     
    
We now have a drug therapy which is effective in HFpEF: Do we still need a device based therapy

I am confused! Out of these 50+ treatment options – when to use what?


17:20 - 18:00   |  Ballroom

Case 1
   
Case 2
   
Case 3
  
Case 4